OBJECTIVES: : Glycogen storage disease (GSD) type Ib is a congenital disorder of glycogen metabolism that is associated with neutropenia, neutrophil and monocyte dysfunction, and an inflammatory bowel disease (IBD) that mimics a Crohn disease phenotype. The enteric microflora is implicated in the pathogenesis of IBD; however, its role in the development of GSD-associated IBD is unknown. Antibody reactivity to Saccharomyces cerevisiae antibodies (ASCA), Escherichia coli outer membrane porin C (anti-OmpC), and bacterial flagellin (anti-CBir1) have been associated with Crohn disease in the general population, but they have an undetermined association in children and adults with GSD-Ib. Our goal was to examine the association of ASCA, anti-OmpC, and anti-CBir1 with the clinical features of GSD-Ib enterocolitis. PATIENTS AND METHODS: : A retrospective review identified 19 patients with GSD-Ib with or without a known diagnosis of enterocolitis. Radiographic, endoscopic, and serologic data were collected and assays for ASCA, anti-OmpC, and anti-CBir1 obtained. RESULTS: : Seven patients had combined radiographic, endoscopic, and histologic evidence of intestinal inflammation; the majority had ileocolonic involvement. Seventeen of 19 (89%) patients had elevated anti-CBir1 levels (6/7 in the IBD group and 11/12 in the no clinical evidence of IBD group). Thirteen of 19 (68%) had elevated anti-OmpC levels (5/7 in the IBD group and 8/12 in the no clinical evidence of IBD group). Eleven of 19 (58%) patients had elevated ASCA IgA levels (4/7 in the IBD group and 7/12 in the no clinical evidence of IBD group). CONCLUSIONS: : Nearly all of the patients with GSD-Ib had elevated anti-CBir1 levels. The antibody did not differentiate those with and without a diagnosis of GSD-Ib-associated IBD. Seroreactivity to flagellin may represent immune dysfunction rather than active enterocolitis in this patient population. Long-term follow-up of the group without known IBD is required to determine whether these antibodies can predict intestinal inflammation.
OBJECTIVES: : Glycogen storage disease (GSD) type Ib is a congenital disorder of glycogen metabolism that is associated with neutropenia, neutrophil and monocyte dysfunction, and an inflammatory bowel disease (IBD) that mimics a Crohn disease phenotype. The enteric microflora is implicated in the pathogenesis of IBD; however, its role in the development of GSD-associated IBD is unknown. Antibody reactivity to Saccharomyces cerevisiae antibodies (ASCA), Escherichia coli outer membrane porin C (anti-OmpC), and bacterial flagellin (anti-CBir1) have been associated with Crohn disease in the general population, but they have an undetermined association in children and adults with GSD-Ib. Our goal was to examine the association of ASCA, anti-OmpC, and anti-CBir1 with the clinical features of GSD-Ib enterocolitis. PATIENTS AND METHODS: : A retrospective review identified 19 patients with GSD-Ib with or without a known diagnosis of enterocolitis. Radiographic, endoscopic, and serologic data were collected and assays for ASCA, anti-OmpC, and anti-CBir1 obtained. RESULTS: : Seven patients had combined radiographic, endoscopic, and histologic evidence of intestinal inflammation; the majority had ileocolonic involvement. Seventeen of 19 (89%) patients had elevated anti-CBir1 levels (6/7 in the IBD group and 11/12 in the no clinical evidence of IBD group). Thirteen of 19 (68%) had elevated anti-OmpC levels (5/7 in the IBD group and 8/12 in the no clinical evidence of IBD group). Eleven of 19 (58%) patients had elevated ASCA IgA levels (4/7 in the IBD group and 7/12 in the no clinical evidence of IBD group). CONCLUSIONS: : Nearly all of the patients with GSD-Ib had elevated anti-CBir1 levels. The antibody did not differentiate those with and without a diagnosis of GSD-Ib-associated IBD. Seroreactivity to flagellin may represent immune dysfunction rather than active enterocolitis in this patient population. Long-term follow-up of the group without known IBD is required to determine whether these antibodies can predict intestinal inflammation.
Authors: Konstantinos A Papadakis; Huiying Yang; Andrew Ippoliti; Ling Mei; Charles O Elson; Robert M Hershberg; Eric A Vasiliauskas; Phillip R Fleshner; Maria T Abreu; Kent Taylor; Carol J Landers; Jerome I Rotter; Stephan R Targan Journal: Inflamm Bowel Dis Date: 2007-05 Impact factor: 5.325
Authors: Adria A Condino; Edward J Hoffenberg; Frank Accurso; Chureeporn Penvari; Meg Anthony; Jane Gralla; Judith A O'Connor Journal: J Pediatr Gastroenterol Nutr Date: 2005-07 Impact factor: 2.839
Authors: Srinivasan Ramanuja; Karen M Wolf; Mohammed A Sadat; Stephen J Mahoney; Mary C Dinauer; Robert P Nelson Journal: Ann Allergy Asthma Immunol Date: 2005-08 Impact factor: 6.347
Authors: Stephan R Targan; Carol J Landers; Huiying Yang; Michael J Lodes; Yingzi Cong; Konstantinos A Papadakis; Eric Vasiliauskas; Charles O Elson; Robert M Hershberg Journal: Gastroenterology Date: 2005-06 Impact factor: 22.682
Authors: Marla C Dubinsky; Subra Kugathasan; Ling Mei; Yoana Picornell; Justin Nebel; Iwona Wrobel; Antonio Quiros; Gary Silber; Ghassan Wahbeh; Lirona Katzir; Eric Vasiliauskas; Ron Bahar; Anthony Otley; David Mack; Jonathan Evans; Joel Rosh; Maria Oliva Hemker; Neal Leleiko; Wallace Crandall; Christine Langton; Carol Landers; Kent D Taylor; Stephan R Targan; Jerome I Rotter; James Markowitz; Jeffrey Hyams Journal: Clin Gastroenterol Hepatol Date: 2008-07-10 Impact factor: 11.382
Authors: Michael J Lodes; Yingzi Cong; Charles O Elson; Raodoh Mohamath; Carol J Landers; Stephan R Targan; Madeline Fort; Robert M Hershberg Journal: J Clin Invest Date: 2004-05 Impact factor: 14.808